Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis

• Main Authors: Junzhen Wu (Author), Xinyi Yang (Author), Jufang Wu (Author), Jingjing Wang (Author), Hailan Wu (Author), Yu Wang (Author), Hong Yuan (Author), Huahui Yang (Author), Hailin Wang (Author), Jing Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Contezolid is an oxazolidinone antimicrobial agent newly approved for treatment of Gram-positive bacterial infections. It is primarily metabolized by the liver. This study aimed to assess whether it is required to adjust the dose of contezolid in patients with moderate hepatic impairment...